Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres.

[1]  E. Majerová,et al.  Highly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length. , 2017, Cell reports.

[2]  Jennie W. Taylor,et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.

[3]  Shivashankar H. Nagaraj,et al.  Whole-genome landscape of pancreatic neuroendocrine tumours , 2017, Nature.

[4]  E. Lazzerini Denchi,et al.  TZAP: A telomere-associated protein involved in telomere length control , 2017, Science.

[5]  L. Lau,et al.  The C-Circle Assay for alternative-lengthening-of-telomeres activity. , 2017, Methods.

[6]  T. Fujiwara,et al.  Spatiotemporal analysis with a genetically encoded fluorescent RNA probe reveals TERRA function around telomeres , 2016, Scientific Reports.

[7]  P. Raman,et al.  Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.

[8]  T. de Lange,et al.  Telomere-Internal Double-Strand Breaks Are Repaired by Homologous Recombination and PARP1/Lig3-Dependent End-Joining. , 2016, Cell reports.

[9]  R. Greenberg,et al.  Break-induced telomere synthesis underlies alternative telomere maintenance , 2016, Nature.

[10]  M. Kleiter,et al.  Telomere Transcripts Target Telomerase in Human Cancer Cells , 2016, Genes.

[11]  E. Gilson,et al.  TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for Chromosome-End Protection. , 2016, Molecular cell.

[12]  Leanne S. Whitmore,et al.  Human CST Facilitates Genome-wide RAD51 Recruitment to GC-Rich Repetitive Sequences in Response to Replication Stress. , 2016, Cell reports.

[13]  D. Zwijnenburg,et al.  Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors , 2016 .

[14]  Simon C Watkins,et al.  Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.

[15]  R. Greenberg,et al.  ALTernative Telomere Maintenance and Cancer. , 2015, Trends in cancer.

[16]  J. Shay,et al.  A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells , 2015, Oncoscience.

[17]  P. Mieczkowski,et al.  Essential role for polymerase specialization in cellular nonhomologous end joining , 2015, Proceedings of the National Academy of Sciences.

[18]  D. Higgs,et al.  Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX , 2015, Nature Communications.

[19]  M. Fischer,et al.  Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. , 2015, Biomedical reports.

[20]  Justin B Kinney,et al.  Concerted activities of Mcm4, Sld3, and Dbf4 in control of origin activation and DNA replication fork progression , 2015, bioRxiv.

[21]  Gudrun Schleiermacher,et al.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.

[22]  Sven Rahmann,et al.  Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.

[23]  D. Korzhnev,et al.  HLTF's Ancient HIRAN Domain Binds 3' DNA Ends to Drive Replication Fork Reversal. , 2015, Molecular cell.

[24]  Y. Jeng,et al.  Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas , 2015, Modern Pathology.

[25]  Chibo Hong,et al.  The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.

[26]  M. Lei,et al.  SLX4 contributes to telomere preservation and regulated processing of telomeric joint molecule intermediates , 2015, Nucleic acids research.

[27]  Michael D. Stone,et al.  The telomerase essential N-terminal domain promotes DNA synthesis by stabilizing short RNA–DNA hybrids , 2015, Nucleic acids research.

[28]  V. Plagnol,et al.  Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. , 2015, The Journal of clinical investigation.

[29]  R. Reddel,et al.  ATRX represses alternative lengthening of telomeres , 2015, Oncotarget.

[30]  Ludovic C. Gillet,et al.  Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps , 2015, Nature Medicine.

[31]  V. Pistoia,et al.  Intratumoral diversity of telomere length in individual neuroblastoma tumors , 2014, Oncotarget.

[32]  E. Larsson,et al.  Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types , 2014, Nature Genetics.

[33]  E. Yamaoka,et al.  Clinical features of ATRX or DAXX mutated neuroblastoma. , 2014, Journal of pediatric surgery.

[34]  C. Azzalin,et al.  RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells , 2014, Nature Communications.

[35]  S. Savage,et al.  Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1 , 2014, Genes & development.

[36]  R. Greenberg,et al.  Interchromosomal Homology Searches Drive Directional ALT Telomere Movement and Synapsis , 2014, Cell.

[37]  D. Pisano,et al.  Identification of TERRA locus unveils a telomere protection role through association to nearly all chromosomes , 2014, Nature Communications.

[38]  H. Pickett,et al.  NuRD–ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination , 2014, Nature Structural &Molecular Biology.

[39]  S. West,et al.  MUS81-EME2 Promotes Replication Fork Restart , 2014, Cell reports.

[40]  J. Shay,et al.  Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations , 2014, Journal of Neuro-Oncology.

[41]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[42]  Jin-Qiu Zhou,et al.  Telomere Recombination Preferentially Occurs at Short Telomeres in Telomerase-Null Type II Survivors , 2014, PloS one.

[43]  Jing-Jer Lin,et al.  Telomeric transcripts stimulate telomere recombination to suppress senescence in cells lacking telomerase , 2014, Proceedings of the National Academy of Sciences.

[44]  I. Draškovič,et al.  Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin , 2014, Nucleic acids research.

[45]  G. Almouzni,et al.  Rapid induction of Alternative Lengthening of Telomeres by depletion of the histone chaperone ASF1 , 2013, Nature Structural &Molecular Biology.

[46]  H. Kurumizaka,et al.  Telomeric repeats act as nucleosome-disfavouring sequences in vivo , 2013, Nucleic acids research.

[47]  Min Yu,et al.  Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: Impact on telomere maintenance, genomic instability, and tumor growth , 2013, Oncogene.

[48]  Shankar Balasubramanian,et al.  Visualization and selective chemical targeting of RNA G-quadruplex structures in the cytoplasm of human cells. , 2014, Nature chemistry.

[49]  S. Boulton,et al.  RTEL1 Is a Replisome-Associated Helicase That Promotes Telomere and Genome-Wide Replication , 2013, Science.

[50]  Bettina Balk,et al.  Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence , 2013, Nature Structural &Molecular Biology.

[51]  Yong Chen,et al.  SLX4 Assembles a Telomere Maintenance Toolkit by Bridging Multiple Endonucleases with Telomeres , 2013, Cell reports.

[52]  M. Blasco,et al.  Localization-Dependent and -Independent Roles of SLX4 in Regulating Telomeres , 2013, Cell reports.

[53]  J. Schug,et al.  Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal–Hreidarsson syndrome , 2013, Proceedings of the National Academy of Sciences.

[54]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[55]  M. Ruden,et al.  Novel anticancer therapeutics targeting telomerase. , 2013, Cancer treatment reviews.

[56]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[57]  A. Naranjo,et al.  Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group , 2013, The Journal of Nuclear Medicine.

[58]  Sara Sandin,et al.  Structure of Active, Dimeric Human Telomerase , 2013, Nature Structural &Molecular Biology.

[59]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[60]  F. Berthold,et al.  Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[62]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[63]  Amy Y. M. Au,et al.  Detection of alternative lengthening of telomeres by telomere quantitative PCR , 2012, Nucleic acids research.

[64]  H. Pickett,et al.  Alternative lengthening of telomeres in normal mammalian somatic cells. , 2013, Genes & development.

[65]  H. Pickett,et al.  Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells , 2012, The Journal of cell biology.

[66]  Rebecca A Dagg,et al.  Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres , 2012, PloS one.

[67]  H. Riethman,et al.  A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection , 2012, The EMBO journal.

[68]  J. Maris,et al.  Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study , 2012, Clinical Cancer Research.

[69]  W. Wright,et al.  Human CST promotes telomere duplex replication and general replication restart after fork stalling , 2012, The EMBO journal.

[70]  A. Decottignies,et al.  Telomere length regulates TERRA levels through increased trimethylation of telomeric H3K9 and HP1α , 2012, Nature Structural &Molecular Biology.

[71]  H. Pickett,et al.  RTEL1 contributes to DNA replication and repair and telomere maintenance , 2012, Molecular biology of the cell.

[72]  W. Hahn,et al.  Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway , 2012, PLoS genetics.

[73]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[74]  Sandy Chang,et al.  CTC1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion , 2012, The EMBO journal.

[75]  H. Pickett,et al.  Telomerase Recruitment Requires both TCAB1 and Cajal Bodies Independently , 2012, Molecular and Cellular Biology.

[76]  C. Schildkraut,et al.  Human telomeres replicate using chromosome-specific, rather than universal, replication programs , 2012, The Journal of cell biology.

[77]  Hongtao Yu,et al.  Scc1 sumoylation by Mms21 promotes sister chromatid recombination through counteracting Wapl. , 2012, Genes & development.

[78]  H. Pickett,et al.  The role of telomere trimming in normal telomere length dynamics , 2012, Cell cycle.

[79]  M. Raíces,et al.  Organismal propagation in the absence of a functional telomerase pathway in Caenorhabditis elegans , 2012, The EMBO journal.

[80]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[81]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[82]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[83]  Jonathan E. Dickerson,et al.  Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus , 2012, Nature Genetics.

[84]  S. Aamdal,et al.  Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial , 2011, Clinical Cancer Research.

[85]  Amy Y. M. Au,et al.  Normal mammalian cells negatively regulate telomere length by telomere trimming. , 2011, Human molecular genetics.

[86]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  L. Haracska,et al.  Coordinated protein and DNA remodeling by human HLTF on stalled replication fork , 2011, Proceedings of the National Academy of Sciences.

[88]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[89]  Katrin Paeschke,et al.  DNA Replication through G-Quadruplex Motifs Is Promoted by the Saccharomyces cerevisiae Pif1 DNA Helicase , 2011, Cell.

[90]  S. Chanock,et al.  Constitutional telomerase mutations are genetic risk factors for cirrhosis , 2011, Hepatology.

[91]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[92]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[93]  Joseph T. Glessner,et al.  Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci , 2011, PLoS genetics.

[94]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[95]  Nazneen Rahman,et al.  Integrative genomics identifies LMO1 as a neuroblastoma oncogene , 2011, Nature.

[96]  Sandy Chang,et al.  TERRA and hnRNPA1 Orchestrate an RPA-to-POT1 Switch on Telomeric Single-Stranded DNA , 2010, Nature.

[97]  R. Collins,et al.  Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML) , 2010 .

[98]  T. de Lange,et al.  A Shld1-controlled POT1a provides support for repression of ATR signaling at telomeres through RPA exclusion. , 2010, Molecular cell.

[99]  J. Mora,et al.  Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma , 2010, Molecular Cancer.

[100]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[101]  R. Reddel,et al.  Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers , 2010, FEBS letters.

[102]  T. de Lange,et al.  Apollo contributes to G overhang maintenance and protects leading-end telomeres. , 2010, Molecular cell.

[103]  J. Lingner,et al.  Molecular Dissection of Telomeric Repeat-Containing RNA Biogenesis Unveils the Presence of Distinct and Multiple Regulatory Pathways , 2010, Molecular and Cellular Biology.

[104]  Stuart L Schreiber,et al.  Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres , 2010, Nature Structural &Molecular Biology.

[105]  A. Multani,et al.  The function of classical and alternative non‐homologous end‐joining pathways in the fusion of dysfunctional telomeres , 2010, The EMBO journal.

[106]  M. Komiyama,et al.  Telomeric repeat-containing RNA structure in living cells , 2010, Proceedings of the National Academy of Sciences.

[107]  C. Allis,et al.  Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres , 2010, Proceedings of the National Academy of Sciences.

[108]  Jing Wang,et al.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence , 2010, Nature.

[109]  E. Gilson,et al.  SNMIB/Apollo protects leading‐strand telomeres against NHEJ‐mediated repair , 2010, The EMBO journal.

[110]  Gudrun Schleiermacher,et al.  Accumulation of segmental alterations determines progression in neuroblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  A. Hamiche,et al.  The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. , 2010, Genes & development.

[112]  S. Keir,et al.  Initial testing of topotecan by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.

[113]  E. Gilson,et al.  Replication Timing of Human Telomeres Is Chromosome Arm–Specific, Influenced by Subtelomeric Structures and Connected to Nuclear Localization , 2010, PLoS genetics.

[114]  G. Celli,et al.  Loss of Rap1 Induces Telomere Recombination in the Absence of NHEJ or a DNA Damage Signal , 2010, Science.

[115]  M. Blasco,et al.  p53 Prevents Entry into Mitosis with Uncapped Telomeres , 2010, Current Biology.

[116]  S. Rafii,et al.  Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions , 2010, Cell.

[117]  J. Bartek,et al.  Cytokine expression and signaling in drug-induced cellular senescence , 2010, Oncogene.

[118]  Raymond L. Stallings,et al.  Global MYCN Transcription Factor Binding Analysis in Neuroblastoma Reveals Association with Distinct E-Box Motifs and Regions of DNA Hypermethylation , 2009, PloS one.

[119]  E. Hiyama,et al.  Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres. , 2009, Journal of pediatric surgery.

[120]  Amy Y. M. Au,et al.  DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity , 2009, Nature Biotechnology.

[121]  R. Chawla,et al.  CpG-island promoters drive transcription of human telomeres. , 2009, RNA.

[122]  H. Pickett,et al.  Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions , 2009, Nature Structural &Molecular Biology.

[123]  L. Haracska,et al.  Role of Double-Stranded DNA Translocase Activity of Human HLTF in Replication of Damaged DNA , 2009, Molecular and Cellular Biology.

[124]  R. Collins,et al.  Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT. , 2009 .

[125]  P. Argani,et al.  The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression , 2009, Modern Pathology.

[126]  M. Blasco,et al.  Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. , 2009, Genes & development.

[127]  Akiko Sakai,et al.  The XNP remodeler targets dynamic chromatin in Drosophila , 2009, Proceedings of the National Academy of Sciences.

[128]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[129]  R. Reddel,et al.  Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins , 2009, The Journal of cell biology.

[130]  J Khan,et al.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee , 2009, British Journal of Cancer.

[131]  J. Shay,et al.  Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas. , 2009, The Journal of bone and joint surgery. American volume.

[132]  S. West,et al.  TRF2 promotes, remodels and protects telomeric Holliday junctions , 2009, The EMBO journal.

[133]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  S. Stewart,et al.  FEN1 contributes to telomere stability in ALT-positive tumor cells , 2009, Oncogene.

[135]  H. Pickett,et al.  Control of telomere length by a trimming mechanism that involves generation of t-circles , 2009, The EMBO journal.

[136]  M. Blasco,et al.  Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. , 2009, Cell stem cell.

[137]  K. Matthay,et al.  Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Robert E. Kingston,et al.  Purification of Proteins Associated with Specific Genomic Loci , 2009, Cell.

[139]  H. Pickett,et al.  Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription , 2009, Nucleic acids research.

[140]  R. Arceci.  The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report , 2009 .

[141]  D. Spector,et al.  53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility , 2008, Nature.

[142]  N. Munshi,et al.  Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM) , 2008 .

[143]  I. Horikawa,et al.  Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence , 2008, Epigenetics & Chromatin.

[144]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[145]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[146]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[147]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[148]  Y. Segev,et al.  Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions. , 2008, Human molecular genetics.

[149]  Timothy M. Errington,et al.  Disease-Associated Human Telomerase RNA Variants Show Loss of Function for Telomere Synthesis without Dominant-Negative Interference , 2008, Molecular and Cellular Biology.

[150]  N. Zaffaroni,et al.  Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT‐associated PML bodies , 2008, International journal of cancer.

[151]  H. Pickett,et al.  Amplification of telomerase reverse transcriptase gene in human mammary epithelial cells with limiting telomerase RNA expression levels. , 2008, Cancer research.

[152]  T. Giordano,et al.  Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[153]  R. Reddel,et al.  A sensitive direct human telomerase activity assay , 2008, Nature Methods.

[154]  T. Veenstra,et al.  Identification of ATPases Pontin and Reptin as Telomerase Components Essential for Holoenzyme Assembly , 2008, Cell.

[155]  J. Murnane,et al.  Telomeres Acquire Distinct Heterochromatin Characteristics during siRNA-Induced RNA Interference in Mouse Cells , 2008, Current Biology.

[156]  N. Orr,et al.  TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. , 2008, American journal of human genetics.

[157]  R. Reddel,et al.  Disruption of Telomere Maintenance by Depletion of the MRE11/RAD50/NBS1 Complex in Cells That Use Alternative Lengthening of Telomeres* , 2007, Journal of Biological Chemistry.

[158]  M. Haughton,et al.  The nature of telomere fusion and a definition of the critical telomere length in human cells. , 2007, Genes & development.

[159]  P. Klatt,et al.  Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination , 2007, The Journal of cell biology.

[160]  R. Reddel,et al.  DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. , 2007, Cancer research.

[161]  N. Bache,et al.  Protein Composition of Catalytically Active Human Telomerase from Immortal Cells , 2007, Science.

[162]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[163]  Sarah A. Compton,et al.  Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. , 2007, Cancer research.

[164]  F. Berthold,et al.  Topotecan and Etoposide in the Treatment of Relapsed High-risk Neuroblastoma: Results of a Phase 2 Trial , 2007, Journal of pediatric hematology/oncology.

[165]  N. Cheung,et al.  Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  R. Verdun,et al.  The DNA Damage Machinery and Homologous Recombination Pathway Act Consecutively to Protect Human Telomeres , 2006, Cell.

[167]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[168]  G. Gaudernack,et al.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study , 2006, British Journal of Cancer.

[169]  K. Collins,et al.  Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. , 2006, Genes & development.

[170]  R. Bristow,et al.  Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR , 2006, The Journal of cell biology.

[171]  M. Feinmesser,et al.  Telomere length is a prognostic factor in neuroblastoma , 2006, Cancer.

[172]  L. Mariani,et al.  Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. , 2006, Cancer research.

[173]  M. Mitchell,et al.  PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase , 2006, Journal of Cell Science.

[174]  J. Haber,et al.  Break-induced replication and recombinational telomere elongation in yeast. , 2006, Annual review of biochemistry.

[175]  W. Yung,et al.  E2F1 and Telomerase: Alliance in the Dark Side , 2006, Cell cycle.

[176]  D. Dunlap,et al.  Direct observation of DNA distortion by the RSC complex. , 2006, Molecular cell.

[177]  R. DePinho,et al.  Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. , 2005, Genes & development.

[178]  Yen-Pei Christy Chang,et al.  Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[179]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  M. L. Schmidt,et al.  Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  John M Maris,et al.  Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  Jan Postberg,et al.  Telomere end-binding proteins control the formation of G-quadruplex DNA structures in vivo , 2005, Nature Structural &Molecular Biology.

[183]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[184]  A. Patchefsky,et al.  Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas , 2005, Clinical Cancer Research.

[185]  A. Jeffreys,et al.  Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. , 2005, Human molecular genetics.

[186]  R. Reddel,et al.  Suppression of Alternative Lengthening of Telomeres by Sp100-Mediated Sequestration of the MRE11/RAD50/NBS1 Complex , 2005, Molecular and Cellular Biology.

[187]  M. Mceachern,et al.  Abrupt disruption of capping and a single source for recombinationally elongated telomeres in Kluyveromyces lactis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[188]  Dihua Yu,et al.  A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[189]  R. Verdun,et al.  Defective Telomere Lagging Strand Synthesis in Cells Lacking WRN Helicase Activity , 2004, Science.

[190]  B. Chait,et al.  TIN2 Binds TRF1 and TRF2 Simultaneously and Stabilizes the TRF2 Complex on Telomeres* , 2004, Journal of Biological Chemistry.

[191]  J. Griffith,et al.  Telomeric DNA in ALT Cells Is Characterized by Free Telomeric Circles and Heterogeneous t-Loops , 2004, Molecular and Cellular Biology.

[192]  J. Murnane,et al.  Chromosome rearrangements resulting from telomere dysfunction and their role in cancer , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[193]  T. Lange,et al.  Homologous Recombination Generates T-Loop-Sized Deletions at Human Telomeres , 2004, Cell.

[194]  Susan Smith,et al.  A Dynamic Molecular Link between the Telomere Length Regulator TRF1 and the Chromosome End Protector TRF2 , 2004, Current Biology.

[195]  M. Valentine,et al.  Telomerase expression predicts unfavorable outcome in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  K. Wigglesworth,et al.  ATRX, a member of the SNF2 family of helicase/ATPases, is required for chromosome alignment and meiotic spindle organization in metaphase II stage mouse oocytes. , 2004, Developmental biology.

[197]  Jun Qin,et al.  PTOP interacts with POT1 and regulates its localization to telomeres , 2004, Nature Cell Biology.

[198]  S. Oikawa,et al.  Mechanism of Telomere Shortening by Oxidative Stress , 2004, Annals of the New York Academy of Sciences.

[199]  E. Montgomery,et al.  Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. , 2004, The American journal of pathology.

[200]  Peter Sperisen,et al.  Telomere Length Homeostasis Is Achieved via a Switch between Telomerase- Extendible and -Nonextendible States , 2004, Cell.

[201]  B. Armbruster,et al.  Rescue of an hTERT Mutant Defective in Telomere Elongation by Fusion with hPot1 , 2004, Molecular and Cellular Biology.

[202]  L. Cazes,et al.  Alternative Lengthening of Telomeres Is Characterized by High Rates of Telomeric Exchange , 2004, Cancer Research.

[203]  T. Jenuwein,et al.  Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases , 2004, Nature Genetics.

[204]  P. Pandolfi,et al.  Role of PML and the PML-nuclear body in the control of programmed cell death , 2003, Oncogene.

[205]  G. Severi,et al.  A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.

[206]  N. Carter,et al.  A DNA damage checkpoint response in telomere-initiated senescence , 2003, Nature.

[207]  A. Lustig.  Clues to catastrophic telomere loss in mammals from yeast telomere rapid deletion , 2003, Nature Reviews Genetics.

[208]  T. Lange,et al.  DNA Damage Foci at Dysfunctional Telomeres , 2003, Current Biology.

[209]  Masashi Narita,et al.  Reversal of human cellular senescence: roles of the p53 and p16 pathways , 2003, The EMBO journal.

[210]  M. Ladanyi,et al.  Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. , 2003, Cancer research.

[211]  Tamás Kiss,et al.  Modification of Sm small nuclear RNAs occurs in the nucleoplasmic Cajal body following import from the cytoplasm , 2003, The EMBO journal.

[212]  N. Wald,et al.  Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme , 2003 .

[213]  F. Berthold,et al.  Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[214]  M. Urbanek,et al.  Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. , 2002, Cancer research.

[215]  A. Ruíz,et al.  The role of surgery in stage IV neuroblastoma. , 2002, Journal of pediatric surgery.

[216]  A. Jauch,et al.  DNA Ligase IV-Dependent NHEJ of Deprotected Mammalian Telomeres in G1 and G2 , 2002, Current Biology.

[217]  J. Shay,et al.  Human Telomerase and Its Regulation , 2002, Microbiology and Molecular Biology Reviews.

[218]  Anjanabha Saha,et al.  Chromatin remodeling by RSC involves ATP-dependent DNA translocation. , 2002, Genes & development.

[219]  T. Vulliamy,et al.  Association between aplastic anaemia and mutations in telomerase RNA , 2002, The Lancet.

[220]  A. Smogorzewska,et al.  Senescence Induced by Altered Telomere State, Not Telomere Loss , 2002, Science.

[221]  H. Pickett,et al.  Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells , 2002, Nature Genetics.

[222]  高倉 正博.  Cloning of human telomerase catalytic subunit(hTERT)gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells , 2002 .

[223]  Karl Mechtler,et al.  Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability , 2001, Cell.

[224]  D. Stram,et al.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors , 2001, Cancer.

[225]  M. Cerone,et al.  Telomere maintenance by telomerase and by recombination can coexist in human cells. , 2001, Human molecular genetics.

[226]  R. Reddel,et al.  Coexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells , 2001, Molecular and Cellular Biology.

[227]  P. Baumann,et al.  Pot1, the Putative Telomere End-Binding Protein in Fission Yeast and Humans , 2001, Science.

[228]  T. Vulliamy,et al.  Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita. , 2001, Blood cells, molecules & diseases.

[229]  A. Godwin,et al.  ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. , 2000, Journal of cell science.

[230]  R. Reddel,et al.  Telomere maintenance by recombination in human cells , 2000, Nature Genetics.

[231]  A. Zetterberg,et al.  Frequent amplification of the telomerase reverse transcriptase gene in human tumors. , 2000, Cancer research.

[232]  Lynda Chin,et al.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice , 2000, Nature.

[233]  R. Reddel.  The role of senescence and immortalization in carcinogenesis. , 2000, Carcinogenesis.

[234]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[235]  A. Poustka,et al.  Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal‐Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1 , 1999, British journal of haematology.

[236]  N. Tsuyama,et al.  Telomerase activity in hybrids between telomerase-negative and telomerase-positive immortal human cells is repressed in the different complementation groups but not in the same complementation group of immortality , 1999, Mechanisms of Ageing and Development.

[237]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[238]  D. Stram,et al.  Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.

[239]  R. Reddel,et al.  Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. , 1999, Cancer research.

[240]  F. Speleman,et al.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. , 1999, The New England journal of medicine.

[241]  R. Dalla‐Favera,et al.  Direct activation of TERT transcription by c-MYC , 1999, Nature Genetics.

[242]  M. Egholm,et al.  Single base discrimination of CENP-B repeats on mouse and human Chromosomes with PNA-FISH , 1999, Mammalian Genome.

[243]  W. Hahn,et al.  Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[244]  S. Kyo,et al.  Expression of telomerase activity in human endometrium is localized to epithelial glandular cells and regulated in a menstrual phase-dependent manner correlated with cell proliferation. , 1998, The American journal of pathology.

[245]  M. Mann,et al.  Cbf5p, a potential pseudouridine synthase, and Nhp2p, a putative RNA-binding protein, are present together with Gar1p in all H BOX/ACA-motif snoRNPs and constitute a common bipartite structure. , 1998, RNA.

[246]  M. Caizergues-Ferrer,et al.  Nhp2p and Nop10p are essential for the function of H/ACA snoRNPs , 1998, The EMBO journal.

[247]  S. Groshen,et al.  Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. , 1998, Cancer research.

[248]  D. Levy,et al.  Proto-oncogene PML controls genes devoted to MHC class I antigen presentation , 1998, Nature.

[249]  J. Roh,et al.  Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. , 1998, International journal of oncology.

[250]  A. Maitra,et al.  Expression of the RNA component of telomerase during human development and differentiation. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[251]  R. Simon,et al.  Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. , 1998, British Journal of Cancer.

[252]  S. Klauck,et al.  X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions , 1998, Nature Genetics.

[253]  Bas van Steensel,et al.  TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.

[254]  M. Haas,et al.  Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[255]  R. Reddel,et al.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines , 1997, Nature Medicine.

[256]  J. Shay,et al.  Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour? , 1997, European journal of cancer.

[257]  K. Matthay,et al.  Telomerase expression in primary neuroblastomas. , 1997, European journal of cancer.

[258]  T. Rebbeck,et al.  Molecular genetic analysis of familial neuroblastoma. , 1997, European journal of cancer.

[259]  D. Broccoli,et al.  Human telomeres contain two distinct Myb–related proteins, TRF1 and TRF2 , 1997, Nature Genetics.

[260]  E. Gilson,et al.  Telomeric localization of TRF2, a novel human telobox protein , 1997, Nature Genetics.

[261]  Max M. van Noesel,et al.  Neuroblastoma 4S , 1997, Cancer.

[262]  L. Giudice,et al.  Developmental regulation of telomerase activity in human fetal tissues during gestation. , 1997, Molecular human reproduction.

[263]  R. Weinberg,et al.  hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization , 1997, Cell.

[264]  R. Weinberg,et al.  The catalytic subunit of yeast telomerase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[265]  H. Tanke,et al.  Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[266]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[267]  L. Chung,et al.  Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. , 1997, Cancer research.

[268]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[269]  J. Langmore,et al.  Long G Tails at Both Ends of Human Chromosomes Suggest a C Strand Degradation Mechanism for Telomere Shortening , 1997, Cell.

[270]  Gregg B. Morin,et al.  Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT , 1997, Nature Genetics.

[271]  T. Lendvay,et al.  Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes. , 1996, Genetics.

[272]  D. Higgs,et al.  ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. , 1996, Human molecular genetics.

[273]  J. Shay,et al.  Telomerase activity in human intestine. , 1996, International journal of oncology.

[274]  B. Gallie,et al.  Development of retinoblastoma in the absence of telomerase activity. , 1996, Journal of the National Cancer Institute.

[275]  P. Boukamp,et al.  Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[276]  J. Shay,et al.  The reactivation of telomerase activity in cancer progression. , 1996, Trends in genetics : TIG.

[277]  J. Shay,et al.  Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. , 1996, Cancer research.

[278]  A. Jeffreys,et al.  Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere. , 1995, The EMBO journal.

[279]  E. Musgrove,et al.  Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. , 1995, Oncogene.

[280]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[281]  R. Reddel,et al.  Telomere elongation in immortal human cells without detectable telomerase activity. , 1995, The EMBO journal.

[282]  R. Reddel,et al.  Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts , 1995, Molecular and cellular biology.

[283]  D. Higgs,et al.  Mutations in a putative global transcriptional regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome) , 1995, Cell.

[284]  J. Shay,et al.  Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP) , 1995 .

[285]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[286]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[287]  J. Bond,et al.  Escape from senescence in human diploid fibroblasts induced directly by mutant p53. , 1994, Oncogene.

[288]  J. Fletcher.  Immortalized Cell Lines , 1994 .

[289]  J. Pelletier,et al.  Absence of p53 gene mutations in primary neuroblastomas. , 1993, Cancer research.

[290]  R. Metcalf,et al.  p53 mutations in human immortalized epithelial cell lines. , 1993, Carcinogenesis.

[291]  R. Reddel,et al.  Assignment of SV40-immortalized cells to more than one complementation group for immortalization. , 1993, Experimental cell research.

[292]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[293]  J. Shay,et al.  A role for both RB and p53 in the regulation of human cellular senescence. , 1991, Experimental cell research.

[294]  H. Cooke,et al.  In vivo loss of telomeric repeats with age in humans. , 1991, Mutation research.

[295]  N. Cheung,et al.  Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. , 1991, Progress in clinical and biological research.

[296]  Barbara L. Billington,et al.  Position effect at S. cerevisiae telomeres: Reversible repression of Pol II transcription , 1990, Cell.

[297]  Robin C. Allshire,et al.  Telomere reduction in human colorectal carcinoma and with ageing , 1990, Nature.

[298]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[299]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[300]  G. Morin.  The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats , 1989, Cell.

[301]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[302]  J. Szostak,et al.  A mutant with a defect in telomere elongation leads to senescence in yeast , 1989, Cell.

[303]  E. Blackburn,et al.  A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis , 1989, Nature.

[304]  W. Gilbert,et al.  Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its implications for meiosis , 1988, Nature.

[305]  Y. Kaneko,et al.  Different karyotypic patterns in early and advanced stage neuroblastomas. , 1987, Cancer research.

[306]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[307]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[308]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[309]  J. Trent,et al.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc , 1984, Nature.

[310]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[311]  R. Holliday,et al.  Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts. , 1983, Journal of cell science.

[312]  A. Tsiatis,et al.  Cytogenetic features of human neuroblastomas and cell lines. , 1981, Cancer research.

[313]  A. Olovnikov.  [Principle of marginotomy in template synthesis of polynucleotides]. , 1971, Doklady Akademii nauk SSSR.

[314]  H. Cannell.  Dyskeratosis congenita. , 1971, The British journal of oral surgery.

[315]  A. Mirsky,et al.  RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[316]  G. Pontecorvo.  Structure of Heterochromatin , 1944, Nature.